---
title: "UNCY: Net loss widened to $14.5M in H1 2026 as FDA again delayed OLC approval over manufacturing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295650763.md"
description: "Net loss for the first half of 2026 rose to $14.5 million, driven by higher R&D and G&A expenses, while the FDA issued a second CRL for OLC due to manufacturing issues. Cash reserves remain strong at $44.2 million, but additional capital will be needed for future development.Original document: Unicycive Therapeutics, Inc. [UNCY] SEC 10-Q Quarterly Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T10:35:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295650763.md)
  - [en](https://longbridge.com/en/news/295650763.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295650763.md)
generator: "portal-rs"
---

# UNCY: Net loss widened to $14.5M in H1 2026 as FDA again delayed OLC approval over manufacturing

Net loss for the first half of 2026 rose to $14.5 million, driven by higher R&D and G&A expenses, while the FDA issued a second CRL for OLC due to manufacturing issues. Cash reserves remain strong at $44.2 million, but additional capital will be needed for future development.

Original document: Unicycive Therapeutics, Inc. \[UNCY\] SEC 10-Q Quarterly Report — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [Canal Ventures CEO Matsuoka spotlights SQUEEZE’s AI-led push to lift hotel productivity at BIPROGY Forum 2026](https://longbridge.com/en/news/296041975.md)
- [Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update](https://longbridge.com/en/news/295797130.md)
- [Unicycive says FDA issues CRL for OLC NDA over third-party manufacturing deficiencies](https://longbridge.com/en/news/291271373.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**